Q3 2025 Celcuity Inc Earnings Call Transcript

Nov 12, 2025 / 09:30 PM GMT

Release Date Price: $85.15 (+7.56%)

Transcript 10-Q8-K

Key Points

Positve

Celcuity Inc (CELC) achieved significant clinical and regulatory milestones, including the release of positive topline data from the PIC 3CA WildType cohort of the phase 3 Victoria 1 study.
The FDA accepted Celcuity Inc (CELC)'s request to submit a new drug application under the real-time oncology review program, potentially expediting the approval process.
Celcuity Inc (CELC) completed concurrent offerings of convertible notes, common stock, and pre-funded warrants, raising approximately $287 million to strengthen its balance sheet.
The company reported promising efficacy results, with the Gatel listed triplet showing a 7.3-month improvement in median progression-free survival compared to the control.
Celcuity Inc (CELC) has made significant progress in preparing for the potential commercial launch of Gatel listed, including hiring key personnel and engaging with payers and decision-makers.

Negative

Celcuity Inc (CELC) reported a net loss of $43.8 million for the third quarter of 2025, an increase from the $29.8 million net loss in the same quarter of 2024.
Research and development expenses increased by $7.3 million, primarily due to higher employee and consulting expenses related to commercial headcount additions.
General and administrative expenses rose significantly to $7.9 million from $2.5 million in the previous year, driven by increased employee and consulting expenses.
The company faces uncertainties regarding the real-time oncology review for the mutant data, as it depends on the clarity and potential impact of the data.
Celcuity Inc (CELC) has not finalized its pricing strategy for Gatel listed, which could impact its market penetration and revenue potential.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CELC.OQ - Celcuity Inc
Q3 2025 Celcuity Inc Earnings Call
Nov 12, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the Calcuity 3rd quarter 2025 financial results webcast and conference call.

At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session.

If at any time during this call you require immediate assistance, please press 0 for the operator.

I would now like to turn the conference over to pour Vucciururi with ICR Healthcare. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you operator, and good afternoon to everyone.

Thank you

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.